Q4 2024 Earnings Call Transcript February 4, 2025 Merck & Co., Inc. misses on earnings expectations. Reported EPS is $1.72 ...

GSK was able to offset the decline thanks to a better-than-expected performance for its cancer medicines and HIV therapeutics ...

Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their ...

The international consulting firm Clarivate makes its bet among the novelties ready for the medicine cabinet this year: three ...

Cases of influenza continue to soar across Canada, meanwhile rates of respiratory syncytial virus, or RSV, and COVID-19 are ...

A data point is marked as “insufficient data” if wastewater samples test negative for a virus (because levels are too low to ...

The novel treatment consists of a single shot which is made of special proteins called antibodies that bind to the site at ...

It’s the season for the sneezin’. Viruses such as Influenza A, RSV and Covid are making their rounds in Tazewell County. While Illinois isn’t ...

US health chiefs issued a warning about RSV jabs, which were only launched in Britain last year.In the UK, the condition is ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

S-337395 is an investigational oral antiviral candidate for RSV infection that inhibits the activity of the L protein, which is essential for virus replication. 1,2 Furthermore, this drug has received ...

Sanofi’s jump in earnings comes with an increased emphasis on R&D and vaccines, plus an eye cast toward M&A to shore up its pipeline.